616 related articles for article (PubMed ID: 9006794)
1. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Gualco L; Schito AM; Schito GC; Marchese A
Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats.
Okuyama Y; Momota K; Morino A
Arzneimittelforschung; 1997 Mar; 47(3):285-92. PubMed ID: 9105547
[TBL] [Abstract][Full Text] [Related]
4. In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
Ozaki M; Matsuda M; Tomii Y; Kimura K; Segawa J; Kitano M; Kise M; Shibata K; Otsuki M; Nishino T
Antimicrob Agents Chemother; 1991 Dec; 35(12):2496-9. PubMed ID: 1667252
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of prulifloxacin. 3rd communication: metabolism in rats, dogs and monkeys.
Okuyama Y; Morino A
Arzneimittelforschung; 1997 Mar; 47(3):293-8. PubMed ID: 9105548
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.
Okuyama Y; Momota K; Morino A
Arzneimittelforschung; 1997 Mar; 47(3):276-84. PubMed ID: 9105546
[TBL] [Abstract][Full Text] [Related]
7. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
[TBL] [Abstract][Full Text] [Related]
8. [In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Araake M; Hara T; Watabe H; Nishino T
Jpn J Antibiot; 2002 Dec; 55(6):778-90. PubMed ID: 12621732
[TBL] [Abstract][Full Text] [Related]
9. In vivo antibacterial activity of a prodrug of NM394, a thiazetoquinoline carboxylic acid derivative.
Ozaki M; Tomii Y; Matsuda M; Segawa J; Kitano M; Kise M; Nishino T
Chemotherapy; 1998; 44(1):21-30. PubMed ID: 9444405
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice.
Obana Y; Nishino T
Drugs Exp Clin Res; 1988; 14(5):327-31. PubMed ID: 3219995
[TBL] [Abstract][Full Text] [Related]
11. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Noviello S; Ianniello F; Leone S; Esposito S
Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
[TBL] [Abstract][Full Text] [Related]
12. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
Montanari MP; Mingoia M; Varaldo PE
Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353
[TBL] [Abstract][Full Text] [Related]
13. In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
Obana Y; Nishino T
Drugs Exp Clin Res; 1989; 15(2):53-8. PubMed ID: 2661182
[TBL] [Abstract][Full Text] [Related]
14. Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
Chen Y; Yang H; Lu G; Wu X; Huang W; Wu Y; Lv X; Wu G; Zhang G; Li Q; Sun Y
Chemotherapy; 2012; 58(3):249-56. PubMed ID: 22890091
[TBL] [Abstract][Full Text] [Related]
15. Prulifloxacin: a new antibacterial fluoroquinolone.
Prats G; Rossi V; Salvatori E; Mirelis B
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
[TBL] [Abstract][Full Text] [Related]
16. Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections.
Carmignani G; De Rose AF; Olivieri L; Salvatori E; Rosignoli MT; Dionisio P
Urol Int; 2005; 74(4):326-31. PubMed ID: 15897698
[TBL] [Abstract][Full Text] [Related]
17. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.
Yoshida T; Mitsuhashi S
Antimicrob Agents Chemother; 1993 Apr; 37(4):793-800. PubMed ID: 8388199
[TBL] [Abstract][Full Text] [Related]
19. [Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Tani M; Maebashi K; Araake M; Watabe H
Jpn J Antibiot; 2002 Dec; 55(6):882-5. PubMed ID: 12621742
[TBL] [Abstract][Full Text] [Related]
20. Prulifloxacin.
Keam SJ; Perry CM
Drugs; 2004; 64(19):2221-34; discussion 2235-6. PubMed ID: 15456336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]